← Back

Wire · operational-macro

FDA approves first drug, Infilbray, for neurological problems in Gaucher

Published

19 November 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at gaucherdiseasenews.com →

◆ Verified

Fusion42 · 19 November 2026 · Fusion42 review

The FDA approved Infilbray (venglustat), developed by Sanofi, as the first treatment targeting neurological symptoms of Gaucher disease type 3 for both adults and children. In clinical trials, Infilbray showed significant improvements in cognition and motor coordination while managing non-neurological symptoms as effectively as existing therapies.

This Wire brief sits within Fusion42's coverage of Biotech, and 7 sources have reported it between 18 Nov 2026 and 20 Nov 2026.

◆ ◆ The Wire takeaway

Neurological care for Gaucher type 3 just opened a new front. If you develop treatments for rare neurological diseases, this FDA approval signals a fresh competitive and partnership landscape.

◆ Coverage

7 sources · first reported 18 Nov 2026 · latest 20 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalrare-diseaseneurological-treatmentsanofigaucher-disease